Biotechnology Catalysts: Positive Phase 2 Results Show Higher Gains Than FDA Approvals


Investment thesis: Biotechnology investors work on the assumption that news surrounding assets in clinical development impact company valuation significantly. Our analysis suggests that focusing on earlier events, such as Phase 2 and 3 data release, represents a stronger short-term, catalyst-based investment strategy in the biotechnology sector, relative to PDUFA events.Read More →